COMPANY PROFILE

TRex Bio

A discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer…

South San Francisco, United StatesFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About TRex Bio

TRexBio is a biotech startup that operates in the field of immune-mediated diseases. The company's primary focus is on modifying diseases at the tissue level to restore tissue homeostasis. They achieve this by leveraging a combination of modern sequencing and computational tools, along with human assay systems, to create innovative therapeutics.

TRexBio serves a market that includes patients suffering from immune-mediated diseases. The company's business model revolves around the development of tissue Treg-focused therapeutics, which are designed to treat these diseases by targeting the inflammatory process and restoring tissue balance.

The company differentiates itself through its unique approach, which combines a deep understanding of human tissue biology with expertise in machine learning and high throughput "-omics". This allows TRexBio to generate a detailed picture of human tissue immunobiology and the pathways that drive disease.

TRexBio also emphasizes a multidisciplinary approach, combining the latest sequencing and computational tools with translational immunology and traditional drug discovery techniques. This approach is underpinned by a diverse team that values differences in backgrounds, opinions, and experiences.

The company generates revenue through the development and sale of its therapeutics. As these therapeutics are designed to treat a wide range of immune-mediated diseases, the potential market for TRexBio's products is substantial.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: South San Francisco, United States
Employees: 61
Open positions: 2
Dealroom signal: 48.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jan 2026	$50M	$420M	Polaris Partners · Alexandria Venture Investments · Janus Henderson Investors · Balyasny Asset Management	↗
SERIES BOther financing	Nov 2024	$84M	$336M	Polaris Partners · Johnson & Johnson Innovation · SV Health Investors · Alexandria Venture Investments	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

TRex Bio website traffic

Latest recorded traffic for TRex Bio is 8.9K monthly website visits, up 147.2% over the last three months. TRex Bio's team grew 5.2% over the past year.

Latest monthly visits8.9K 3-month web change+147.2% 1-year team growth+5.2%

Monthly website visitsJan 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Associate Director, Clinical OperationsSan Francisco, California, United States, Northern America, Americas · Other · Jul 23, 2026 Senior Director, Clinical Data ManagementSouth San Francisco, CA · Data Science & Engineering · Jul 10, 2026 Associate Director, Clinical OperationsSouth San Francisco, CA · Other · Jun 11, 2026 Senior Director, Chemistry, Manufacturing, and ControlsSan Francisco, California, United States · Other · Sep 20, 2025

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAscidian TherapeuticsEnables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time	Boston, United States	Operational	47	$90M	$250M
ATAtalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases	Boston, United States	Operational
CTCartesian TherapeuticsCartesian \| Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian	Gaithersburg, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational